Neu-Sensamide radiation sensitizer: OXGN amended its Phase III clinical trial

The Phase III protocol for Neu-Sensamide will now target squamous cell carcinoma, and will continue to enroll patients only in Europe,

Read the full 213 word article

How to gain access

Continue reading with a
two-week free trial.